TY - JOUR
T1 - Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
T2 - A Systematic Review and Meta-Analysis
AU - Shah, Rajendra P.
AU - Shafiq, Aimen
AU - Hamza, Mohammad
AU - Maniya, Muhammad Talha
AU - Duhan, Sanchit
AU - Keisham, Bijeta
AU - Patel, Bansari
AU - Alamzaib, Sardar Muhammad
AU - Yashi, Kanica
AU - Uppal, Dipan
AU - Sattar, Yasar
AU - Tiwari, Dinesh
AU - Paul, Timir K.
AU - AlJaroudi, Wael
AU - Alraies, M. Chadi
N1 - Publisher Copyright:
© 2023
PY - 2023/11/15
Y1 - 2023/11/15
N2 - Limited data comparing prasugrel and ticagrelor in acute coronary syndrome are available. Online databases, including MEDLINE and Cochrane Central, were queried to compare these drugs. The primary outcomes of this meta-analysis are myocardial infarction (MI), all-cause mortality, cardiovascular mortality, noncardiovascular mortality, stent thrombosis, and stroke. The secondary outcome is major bleeding. A total of 9 studies, including 94,590 patients (prasugrel group = 32,759; ticagrelor group = 61,831), were included in this meta-analysis. The overall mean age was 62.73 years, whereas the mean age for the ticagrelor and prasugrel groups was 63.80 and 61.65 years, respectively. Prasugrel is equally effective as compared with ticagrelor in preventing MI. There was no difference between the 2 groups regarding all-cause mortality, stent thrombosis, stroke, or major bleeding. In patients with acute coronary syndrome, prasugrel is equally effective when compared with ticagrelor in preventing MI.
AB - Limited data comparing prasugrel and ticagrelor in acute coronary syndrome are available. Online databases, including MEDLINE and Cochrane Central, were queried to compare these drugs. The primary outcomes of this meta-analysis are myocardial infarction (MI), all-cause mortality, cardiovascular mortality, noncardiovascular mortality, stent thrombosis, and stroke. The secondary outcome is major bleeding. A total of 9 studies, including 94,590 patients (prasugrel group = 32,759; ticagrelor group = 61,831), were included in this meta-analysis. The overall mean age was 62.73 years, whereas the mean age for the ticagrelor and prasugrel groups was 63.80 and 61.65 years, respectively. Prasugrel is equally effective as compared with ticagrelor in preventing MI. There was no difference between the 2 groups regarding all-cause mortality, stent thrombosis, stroke, or major bleeding. In patients with acute coronary syndrome, prasugrel is equally effective when compared with ticagrelor in preventing MI.
KW - angioplasty
KW - balloon
KW - coronary artery
KW - myocardial infarction
KW - percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85172295023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172295023&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2023.08.117
DO - 10.1016/j.amjcard.2023.08.117
M3 - Review article
C2 - 37751668
AN - SCOPUS:85172295023
SN - 0002-9149
VL - 207
SP - 206
EP - 214
JO - American Journal of Cardiology
JF - American Journal of Cardiology
ER -